News | December 11, 2013

NCKU, Duke University Researchers Successfully Implant a New Cardiac Assist Device on Calf

December 11, 2013 – The National Cheng Kung University Heart Science and Medical Devices Research Center (NCKU HSDMRC) and the Division of Cardiothoracic Surgery, Department of Surgery, Duke University, Durham, NC, USA, jointly carried out a cardiac assist device implantation on a calf in October.

Roberto Manson and Mani Daneshmand from Cardiothoracic Surgery, Duke University Medical Center attended a joint Duke-NCKU workshop on early interventional ventricular assist device hosted by NCKU from October 13-16, and participated in the para-aortic blood pump (PABP) implantation surgery on the calf.

NCKU HSDMRC Director Pong-Jeu Lu, had led his research team to develop the PABP for over thirteen years.

“PABP is a new type of left ventricular assist device which has completed major design, prototype manufacturing and testing after more than 10 years of effort,” Lu said. “It is worthwhile mentioning that PABP is designed to be implanted in patients with heart failure prior to irreversible stage to hopefully restore heart function.”

However, the most important part would be the minimally invasive surgery, which allows rapid implantation into the aorta without affecting heart functions, thus shortening the recovery time after surgery.

Last year, Lu’s research team signed a 3-year agreement with the Division of Cadiothoracic Surgery at Duke University pertaining to the research development of cardiac assist devices, efficacy and safety regarding surgical treatment on patients with heart failure and the pathway of cell recovery after long-term PABP support.

“NCKU’s PABP research outcome can be applied on patients with heart failure of non-refractory stage,” noted Daneshmand. “It can also be used to restore heart function of patients with late stage heart failure and prolong patient’s life with reasonable quality; hence it is a very advanced piece of medical innovation.”

The research entering the phase of human trials within two years is foreseeable.

For more information:

Related Content

Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems | September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems | August 03, 2017 | Dave Fornell
The current generation of...
Siemens, Sensis Vibe hemodynamic system, ACC 2016
Technology | Hemodynamic Monitoring Systems | April 01, 2016
Siemens will unveil a revamped version of its established Sensis hemodynamic system at the 65 th Annual Scientific...
Feature | Hemodynamic Monitoring Systems | January 12, 2016 | Dave Fornell
Beyond measuring blood flow, pressure, oxygen levels and other vital signs in the cardiac catheterization lab, curren
Overlay Init